Gene therapy for thyroid cancer

Bibliography

• FRANCESCHI S, BOYLE P, MAISONNEUVE P et al.: The epidemiology of thyroid carcinoma. Grit. Rev. Oncog. (1993) 4:25–52.
   PubMed Web of Science ®Google Scholar
• GIMM 0: Thyroid cancer. Cancer Lett. (2001) 163:143–156.
   PubMed Web of Science ®Google Scholar
• BAVERSTOCK K, EGLOFF B, PINCHERA A, RUCHTI C, WILLIAMS D: Thyroid cancer after Chernobyl. Nature (1992) 359:21–22.
   PubMed Web of Science ®Google Scholar
• TAN RK, FINLEY RK 3rd, DRISCOLL D, BAKAMJIAN V, HICKS WL JR, SHEDD DP: Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck (1995) 17:41–47.
   PubMed Web of Science ®Google Scholar
• ENG C, MULLIGAN LM: Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumors, and hirschprung disease. Hum. Mutat. (1997) 9:97–109.
   PubMed Web of Science ®Google Scholar
• BARZON L, BONAGURO R, PALU G, BOSCARO M: New perspectives for gene therapy in endocrinology. Ear: I Endocrinol (2000) 143:447–466.
   PubMed Web of Science ®Google Scholar
• DEGROOT LJ, ZHANG R: Gene therapy for thyroid cancer: where do we stand? Clin. Endocrinol Metab. (2001) 86:2923–2928.
   Web of Science ®Google Scholar
• GALANIS E, VILE R, RUSSELL S: Delivery systems intended for M vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev Oncol Hematol (2001) 38:177–192.
   PubMed Web of Science ®Google Scholar
• BRAIDEN V, NAGAYAMA Y, IITAKA M, NAMBA H, NIWA M, YAMASHITA S: Retrovirus-mediated suicide gene/prodrug therapy targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology (1998) 139:3996–3999.
   PubMed Web of Science ®Google Scholar
• •First demonstration of the feasibility of transcriptionally targeted gene therapy for DTCs.
   Google Scholar
• ZHANG R, STRAUS FH, DEGROOT LJ: Cell-specific viral gene therapy of a Hurthle cell tumor. I Clin. Endocrinol Metab. (2002) 87:1407–1414.
   PubMed Web of Science ®Google Scholar
• ZHANG R, STRAUS FH, DEGROOT LJ: Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity. Thyroid (2001) 11:115–123.
   PubMed Web of Science ®Google Scholar
• KITAZONO M, CHUMAN Y, AIKOU T, FOJO T: Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells. Clin. Endocrinol Metab. (2001) 86:834–840.
   Google Scholar
• TAKEDA T, YAMAZAKI M, MINEMURA K et al.:A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas. Cancer Gene Titer. (2002) 9:864–874.
   PubMed Web of Science ®Google Scholar
• BARZON L, BONAGURO R, CASTAGLIUOLO I et al.: Transcriptionally-targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer.' Clin. Endocrinol Metab. (2002) 87:5304–5311.
   Google Scholar
• •In vitro and animal experiments demonstrate the therapeutic efficacy of targeted HSV-TK/IL-2 gene therapy in DTC.
   Google Scholar
• KITAZONO M, CHUMAN Y, AIKOU T, FOJO T: Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cAMP pathway. Int. Cancer (2002) 99:453–459.
   PubMed Web of Science ®Google Scholar
• NAGAYAMA Y, NISHIHARA E, IITAKA M, NAMBA H, YAMASHITA S, NIWA M: Enhanced efficacy of transcriptionally targeted suicide gene/ prodrug therapy for thyroid carcinoma with the Cre-loxP system. Cancer Res. (1999) 59:3049–3052.
   PubMed Web of Science ®Google Scholar
• •The Cre-/oxPsystem, under the control of the thyroglobulin promoter, is used to enhance expression of therapeutic genes in thyroid cancer cells.
   Google Scholar
• SHIMURA H, SUZUKI H, MIYAZAKI A et al.: Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells. Cancer Res. (2001) 61:3640–3646.
   PubMed Web of Science ®Google Scholar
• •Transcriptional targeting of ATC is achieved by co-expression of thyroid transcription factor-1 with TG promoter-driven therapeutic genes.
   Google Scholar
• MINEMURA K, TAKEDA T, MINEMURA K et al.: Cell-specific induction of sensitivity to ganciclovir in medullary thyroid carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Endocrinology (2000) 141:1814–1822.
   PubMed Web of Science ®Google Scholar
• MESSINA M, YU DM, LEAROYD DL, BOTH GW, MOLLOY PL, ROBINSON BG: High level, tissue-specific expression of a modified calcitonin/ calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line. Ma Cell. Endocrinol (2000) 164:219–224.
   PubMed Web of Science ®Google Scholar
• •Construction and characterisation of a chimeric enhancer/promoter sequence of the calcitonin/calcitonin gene-related peptide, showing high efficacy and tissue-specificity in MTC cells.
   Google Scholar
• YAMAZAKI M, ZHANG R, STRAUS FH et al.: Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene The]: (2002) 9:64–74.
   PubMed Web of Science ®Google Scholar
• •Animal experiment to demonstrate the therapeutic efficacy of transcriptionally targeted IL-12 gene therapy for MTC.
   Google Scholar
• YAMAZAKI M, STRAUS FH, MESSINA M et al.: Adenovirus-mediated tumor-specific combined gene therapy using herpes simplex virus thymidine/ ganciclovir system and murine interleukin-12 induces effective antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther. (2004) 11:8–15.
   PubMed Web of Science ®Google Scholar
• FAGIN JA, MATSUO K, KARMAKAR A,CHEN DL, TANG SH, KOEFFLER HP: High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. (1993) 91:179–184.
   PubMed Web of Science ®Google Scholar
• DONGHI R, LONGONI A, PILOTTI S, MICHIELI P, DELLA PORTA G, PIEROTTI MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. (1993) 91:1753–1760.
   PubMed Web of Science ®Google Scholar
• MORETTI F, FARSETTI A, SODDU S et al: p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene (1997) 14:729–740.
   PubMed Web of Science ®Google Scholar
• •Demonstration that restoration of p53 activity in p53-null ATC cells leads to expression of thyroid differentiation genes, cell response to TSH and inhibition of cell proliferation.
   Google Scholar
• FAGIN JA, TANG SH, ZEKI K, DI LAURO R, FUSCO A, GONSKY R: Reexpression of thyroid perwddase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53. Cancer Res. (1996) 56:765–771.
   PubMed Web of Science ®Google Scholar
• ZEKI K, TANAKA Y, MORIMOTO I et al.: Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. Int. J. Cancer (1998) 75:391–395.
   PubMed Web of Science ®Google Scholar
• MORETTI F, NANNI S, FARSETTI A et al: Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status. J. Clin. Endocrinol Metab. (2000) 85:302–308.
   PubMed Web of Science ®Google Scholar
• NAGAYAMA Y, SHIGEMATSU K, NAMBA H, ZEKI K, YAMASHITA S, NIWA M: Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo. Anticancer Res. (2000) 20:2723–2728.
   PubMed Web of Science ®Google Scholar
• NARIMATSU M, NAGAYAMA Y, AKINO K et al.: Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. Clin. Endocrinol Metab. (1998) 83:3668–3672.
   Google Scholar
• BLAGOSKLONNY MV, GIANNAKAKOU P, WOJTOWICZ M et al: Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. Clin. Endocrinol Metab. (1998) 83:2516–2522.
   Google Scholar
• KIM SB, AHN IM, PARK HJ et al: Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck (2001) 23:223–229.
   PubMed Web of Science ®Google Scholar
• IMANISHI R, OHTSURU A, IWAMATSU M et al: A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. Clin. Endocrinol Metab. (2002) 87:4821–4824.
   Google Scholar
• KITAZONO M, ROBEY R, ZHAN Z et al.: Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. I Clin. Endocrinol Metab. (2001) 86:3430–3435.
   PubMed Web of Science ®Google Scholar
• KASTAN MB, ZHAN Q, EL-DEIRY WS et al.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Ceil (1992) 71:587–597.
   PubMed Web of Science ®Google Scholar
• DE SMAELE E, ZAZZERONI F, PAPA S et al.: Induction of Gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature (2001) 414:308–313.
   PubMed Web of Science ®Google Scholar
• CHUNG HK, YI YW, JUNG NC et al.: Gadd45gamma expression is reduced in anaplastic thyroid cancer and its reexpression results in apoptosis. Clin. Endocrinol Metab. (2003) 88:3913–3920.
   Google Scholar
• •Demonstration that the Gadd45yturnour suppressor gene has potential use for gene therapy in ATC.
   Google Scholar
• ZHANG W, HOFFMAN B, LIEBERMANN DA: Ectopic expression of MyD118/Gadd45/CR6 (Gadd45 P/a/y) sensitizes neoplastic cells to genotoxic stress induced apoptosis. hat. J. Oncol (2001) 18:749–757.
   Web of Science ®Google Scholar
• ZHANG L, MARTELLI ML, BATTAGLIA C et al.: Thyroid cell transformation inhibits the expression of a novel rat protein tyrosine phosphatase. Exp. Cell Res. (1997) 235:62–70.
   PubMed Web of Science ®Google Scholar
• TRAPASSO F, IULIANO R, BOCCIA A et al.: Rat protein tyrosine phosphatase Ti suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27 (Kipl) . Ma Cell. Biol. (2000) 20:9236–9246.
   Web of Science ®Google Scholar
• IULIANO R, TRAPASSO F, LE PERA I et al.: An adenovirus carrying the rat protein tyrosine phosphatase Ti suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. Cancer Res. (2003) 63:882–886.
   Google Scholar
• •Demonstration that transduction of the PTPri gene in ATC cells inhibits cell proliferation.
   Google Scholar
• KROLL TG, SARRAF P, PECCIARINI L et al: PAX-8-PPAR1 fusion oncogene in human thyroid carcinoma. Science (2000) 289:1357.
   PubMed Web of Science ®Google Scholar
• •Identification of the PAX8-PPAR-1 fusion oncogene as a tumour-specific molecular event in thyroid tumourigenesis.
   Google Scholar
• OHTA K, ENDO T, HARAGUCHI K, HERSHMAN JM, ONAYA T: Ligands for percodsome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Clin. Endocrine]. Metal,. (2001) 86:2170–2177.
   PubMed Web of Science ®Google Scholar
• MARTELLI ML, IULIANO R, LE PERA I et al: Inhibitory effects of percodsome proliferator-activated receptor gamma on thyroid carcinoma cell growth. I. Clin. Endocrine]. Metal,. (2002) 87:4728–4735.
   PubMed Web of Science ®Google Scholar
• HALACHMI N, HALACHMI S, EVRON E et al: Somatic mutations of the PTENtumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer (1998) 23:239–243.
   PubMed Web of Science ®Google Scholar
• DAHIA PL, MARSH DJ, ZHENG Z et al:Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. (1997) 57:4710–4713.
   PubMed Web of Science ®Google Scholar
• VVENG LP, GIMM 0, KUM JB et al.: Transient ectopic expression of PTENin thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum. Mel Genet. (2001) 10:251–258.
   Google Scholar
• JOST CA, MARIN MC, KAELIN WG JR: p73 is a human p53-related protein that can induce apoptosis. Nature (1997) 389:191–194.
   PubMed Web of Science ®Google Scholar
• FRASCA F, VELLA V, ALOISI A et al.: p73tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res. (2003) 63:5829–5837.
   PubMed Web of Science ®Google Scholar
• RODICKER F, STIEWE T, ZIMMERMANN S, PUTZER BM: Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP7.7induction. Cancer Res. (2001) 61:7052–7055.
   PubMed Web of Science ®Google Scholar
• ONDA M, NAGAI H, YOSHIDA A et al.:Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. J. Hum. Genet. (2004) 49(6):312–318.
   PubMed Web of Science ®Google Scholar
• YAMASAKI L, BRONSON R, WILLIAMS BO, DYSON NJ, HARLOW E, JACKS T: Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rbl (+/-) mice. Nat. Genet. (1998) 18:360–364.
   PubMed Web of Science ®Google Scholar
• STIEWE T, PUTZER BM: Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. (2001) 26:464–469.
   Web of Science ®Google Scholar
• BOSSI G, MAZZARO G, PORRELLO A, CRESCENZI M, SODDU S, SACCHI A: Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene (2004) 23:418–425.
   PubMed Web of Science ®Google Scholar
• MCNEISH IA, BELL SJ, LEMOINE NR: Gene therapy progress and prospects: cancer gene therapy using tumor suppressor genes. Gene Ther. (2004) 11:497–503.
   PubMed Web of Science ®Google Scholar
• BARZON L, BOSCARO M, PALU G: Endocrine aspects of cancer gene therapy. Endocr. Rev (2004) 25:1–44.
   PubMed Web of Science ®Google Scholar
• •Updated review on clinical trials of cancer gene therapy and the potential endocrine side-effects of gene therapy.
   Google Scholar
• SCHULER M, HERRMANN R, DE GREVE JL et al.: Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter Phase II study. j Clin. Once]. (2001) 19:1750–1758.
   Google Scholar
• SWISHER SG, ROTH JA, NEMUNAITIS J et al.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J. Nati Cancer Inst. (1999) 91:763–771.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, SWISHER SG, TIMMONS T et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Gin. Once]. (2000) 18:609–622.
   PubMed Web of Science ®Google Scholar
• SWISHER SG, ROTH JA, KOMAKI R et al.: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. (2003) 9:93–101.
   PubMed Web of Science ®Google Scholar
• KIM DS, MCCABE CJ, BUCHANAN MA, WATKINSON JC: Oncogenes in thyroid cancer. Clin. Otelaryngel. (2003) 28:386–395.
   PubMed Web of Science ®Google Scholar
• LEMOINE NR, MAYALL ES, WILLIAMS ED, THURSTON V, WYNFORD-THOMAS D: Agent-specific ras oncogene activation in rat thyroid tumours. Oncogene (1988) 3:541–544.
   PubMed Web of Science ®Google Scholar
• DEL SENNO L, GAMBARI R, DEGLI UBERTI E et al.: c-myc oncogene alterations in human thyroid carcinomas. Cancer Detect. Prey (1987) 10:159–166.
   PubMedGoogle Scholar
• TERRIER P, SHENG ZM, SCHLUMBERGER M et al.: Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. Br. J. Cancer (1988) 57:43–47.
   PubMed Web of Science ®Google Scholar
• CHALLETON C, BOUNACER A, DU VILLARD JA et al.: Pattern of ras and gsp oncogene mutations in radiation-associated human thyroid tumors. Oncogene (1995) 11:601–603.
   Google Scholar
• RUSSO D, ARTURI F, SCHLUMBERGER M et al.: Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene (1995) 11:1907–1911.
   PubMed Web of Science ®Google Scholar
• GIANCOTTI V, BERLINGIERI MT, DIFIORE PP, FUSCO A, VECCHIO G, CRANE-ROBINSON C: Changes in nuclear proteins on transformation of rat epithelial thyroid cells by a murine sarcoma retrovirus. Cancer Res. (1985) 45:6051–6057.
   PubMed Web of Science ®Google Scholar
• GIANCOTTI V, PANI B, D'ANDREA P et al.: Elevated levels of a specific class of nuclear phosphoproteins in cells transformed with v-ras and v-mos oncogenes and by cotransfection with c-myc and polyoma middle T genes. EMBO (1987) 6:1981–1987.
   Google Scholar
• CHIAPPETTA G, BANDIERA A, BERLINGIERI MT et al.: The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene (1995) 10:1307–1314.
   PubMed Web of Science ®Google Scholar
• CHIAPPETTA G, TALLINI G, DE BIASIO MC et al.: Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. (1998) 58:4193–4198.
   Google Scholar
• MULLIGAN LM, KWOK JB, HEALEY CS et al.: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (1993) 363:458–460.
   PubMed Web of Science ®Google Scholar
• DROSTEN M, PUTZER BM: Gene therapeutic approaches for medullary thyroid carcinoma treatment. I. Mel Med. (2003) 81:411–419.
   PubMed Web of Science ®Google Scholar
• DROSTEN M, FRILLING A, STIEWE T,PUTZER BM: A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery (2002) 132:991–997.
   PubMed Web of Science ®Google Scholar
• DROSTEN M, STIEWE T, PUTZER BM: Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum. Gene The]: (2003) 14:971–982.
   PubMed Web of Science ®Google Scholar
• •Demonstration that adenoviral delivery of a dominant-negative RETmutant gene, under the control of a synthetic C cell-selective calcitonin promoter, is effective against REToncogene-related MTC.
   Google Scholar
• COSMA MP, CARD ONE M, CARLOMAGNO F, COLANTUONI V: Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Ma Cell. Biol. (1998) 18:3321–3329.
   Web of Science ®Google Scholar
• PARTHASARATHY R, COTE GJ, GAGEL RF: Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. (1999) 59:3911–3914.
   PubMed Web of Science ®Google Scholar
• HENNIGE AM, LAMMERS R, HOPPNER W et at Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology (2001) 142:4441–4447.
   PubMed Web of Science ®Google Scholar
• QIAO S, IWASHITA T, FURUKAWA T,YAMAMOTO M, SOBUE G, TAKAHASHI M: Differential effects of leukocyte common antigen-related protein on biochemical and biological activities of RET-MEN2A and RET-MEN2B mutant proteins. Biol. Chem. (2001) 276:9460–9467.
   Web of Science ®Google Scholar
• CERUTTI J, TRAPASSO F, BATTAGLIA C et al.: Block of c-myc expression by antisense oligonucleotides inhibits proliferation of human thyroid carcinoma cell lines. Clin. Cancer Res. (1996) 2:119–126.
   PubMed Web of Science ®Google Scholar
• BERLINGIERI MT, MANFIOLETTI G, SANTORO M et at Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Ma Cell. Biol. (1995) 15:1545–1553.
   Web of Science ®Google Scholar
• SCALA S, PORTELLA G, FEDELE M, CHIAPPETTA G, FUSCO A: Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Nati Acad. Sci. USA (2000) 97:4256–4261.
   PubMed Web of Science ®Google Scholar
• •Selective killing of ATC cells by delivery of the HMGI(Y) antisense sequence.
   Google Scholar
• SEBOLT-LEOPOLD JS, DUDLEY DT, HERRERA R et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med. (1999) 5:810–816.
   PubMed Web of Science ®Google Scholar
• FREEMAN SM et al.: ha vivo studies on the mechanism of the bystander effect. Cancer Gene The]: (1994) 1:326–332.
   Google Scholar
• BARBA D, HARDIN J, SADELAIN M, GAGE FH: Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Nati Acad. ScL USA (1994) 91:4348–4352.
   PubMed Web of Science ®Google Scholar
• MULLEN CA et al.: Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum. Gene Ther. (1998) 9:2019–2030.
   PubMed Web of Science ®Google Scholar
• NISHIHARA E, NAGAYAMA Y, MAWATARI F et al.: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation M vitro and in vivo. Endocrinology (1997) 138:4577–4583.
   PubMed Web of Science ®Google Scholar
• •First animal study reporting the efficacy of suicide gene therapy for thyroid cancer.
   Google Scholar
• TAKEDA T, INABA H, YAMAZAKI M et al: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J. Clin. Endocrinol. Metab. (2003) 88:3531–3538.
   PubMed Web of Science ®Google Scholar
• ZHANG R, DEGROOT LJ: Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid (2000) 10:313–319.
   PubMed Web of Science ®Google Scholar
• JIANG S, ALTMANN A, GRIMM D et al:Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. (2001) 8:469–472.
   PubMed Web of Science ®Google Scholar
• SPITZWEG C, HARRINGTON KJ, PINKE LA, VILE RG, MORRIS JC: The sodium iodide symporter and its potential role in cancer therapy. Clin. Endocrinol. Metab. (2001) 86:3327–3335.
   Google Scholar
• MANDELL RB, MANDELL LZ, LINK CJ JR: Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. (1999) 59:661–668.
   PubMed Web of Science ®Google Scholar
• •Demonstration that N/Sbased gene therapy may have both diagnostic and therapeutic applications for cancer.
   Google Scholar
• GROOT-WASSINK T, ABOAGYE EO, GLASER M, LEMOINE NR, VASSAUX G: Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Hum. Gene Ther. (2002) 13:1723–1735.
   PubMed Web of Science ®Google Scholar
• •In vivo imaging of ectopic NIS expression in xenograft tumour models by positron emission tomography.
   Google Scholar
• MARSEE DK, SHEN DH, MACDONALD LR et al: Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed tomography. Cancer Gene Ther. (2004) 11:121–127.
   PubMed Web of Science ®Google Scholar
• SMIT JW, SCHRODER-VAN DER ELST JP, KARPERIEN M, QUE I, ROMIJN JA, VAN DER HEIDE D: Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma. Exp. Clin. Endocrinol. Diabetes (2001) 109:52–55.
   PubMed Web of Science ®Google Scholar
• SMIT JVV, SCHRODER-VAN DER ELST JP, KARPERIEN M et al: Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a NIS defective human thyroid carcinoma cell line. Thyroid (2000) 10:939–943.
   PubMed Web of Science ®Google Scholar
• SMIT JW, SCHRODER-VAN DER ELST JP, KARPERIEN M et atIodide kinetics and experimental 1311 therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J. Clin. Endocrinol. Metab. (2002) 87:1247–1253.
   PubMed Web of Science ®Google Scholar
• HUANG M, BATRA RK, KOGAI T et al.: Ectopic expression of the thyropercoddase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. (2001) 8:612–618.
   PubMed Web of Science ®Google Scholar
• HABERKORN U: Gene therapy with sodium/iodide symporter in hepatocarcinoma. Exp. Clin. Endocrinol. Diabetes (2001) 109:60–62.
   PubMed Web of Science ®Google Scholar
• BOLAND A, MAGNON C, FILETTI S et al.: Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid (2002) 12:19–26.
   PubMed Web of Science ®Google Scholar
• BOYD M, CUNNINGHAM SH, BROWN M, MAIRS RJ, WHELDON TE: Noradrenaline transporter gene transfer for radiation cell kill by 1311 meta-iodobenzylguanidine. Gene The]: (1999) 6:1147–1152.
   PubMed Web of Science ®Google Scholar
• BOYD M, MAIRS SC, STEVENSON K et al: Transfected mosaic spheroids: a new model for evaluation of tumour cell killing in targeted radiotherapy and experimental gene therapy. J. Gene Med. (2002) 4:567–576.
   PubMed Web of Science ®Google Scholar
• SOLER MN, BOBE P, BENIHOUD K, LEMAIRE G, ROOS BA, LAUSSON S: Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J. Gene Med. (2000) 2:344–352.
   PubMed Web of Science ®Google Scholar
• RAINOV NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene The]: (2000) 11:2389–2401.
   Google Scholar
• LAUSSON S, FOURNES B, BORREL C, MILHAUD G, TREILHOU-LAHILLE F: Immune response against medullary thyroid carcinoma (MTC) induced by parental and/ or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma. Cancer Immunol. Immunother: (1996) 43:116–123.
   Google Scholar
• ZHANG R, BAUNOCH D, DEGROOT LJ: Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid (1998) 8:1137–1146.
   PubMed Web of Science ®Google Scholar
• ZHANG R, STRAUS FH, DEGROOT LJ: Effective genetic therapy of established medullary thyroid carcinoma with murine interleukin-2: dissemination and cytotoxicity studies in a rat tumor model. Endocrinology (1999) 140:2152–2158.
   PubMed Web of Science ®Google Scholar
• •Animal study demonstrating that adenoviral vector-mediated delivery of IL-2 can efficiently eradicate xenograft MTC and confer immunity against rechallenge with wild-type tumor cells. No significant toxicity of IL-2 gene therapy to other organs.
   Google Scholar
• ZHANG R, DEGROOT LJ: Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin-12 subunits in a rat medullary thyroid carcinoma model. Clin. Endocrinol. (Oxf) (2000) 52:687–694.
   PubMed Web of Science ®Google Scholar
• SHI Y, PARHAR RS, ZOU M et al.: Gene therapy of anaplastic thyroid carcinoma with a single-chain interleukin-12 fusion protein. Hum. Gene Thec (2003) 14:1741–1751.
   PubMed Web of Science ®Google Scholar
• •Demonstration of efficacy of IL-12 gene therapy for ATC in a tumor xenograft model in nude mice. The antitumour activity was mainly mediated by natural killer cells.
   Google Scholar
• SOLER MN, MILHAUD G, LEKMINE F, TREILHOU-LAHILLE F, KLATZMANN D, LAUSSON S: Treatment of medullary thyroid carcinoma by combined expression of suicide and interleukin-2 genes. Cancer Immunol. Immunother. (1999) 48:91–99.
   PubMed Web of Science ®Google Scholar
• ZHANG R, DEGROOT LJ: An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin-2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma. Endocc Relat. Cancer (2001) 8:315–325.
   PubMed Web of Science ®Google Scholar
• •Development of an adenoviral vector expressing both HSV-TK and h/L-2for gene therapy of MTC and demonstration of an antiturnour effect superior to that of each single therapeutic gene given alone.
   Google Scholar
• BARZON L, BONAGURO R, CASTAGLIUOLO I et al.: Gene therapy of thyroid cancer via retrovirally-driven combined expression of human interleukin-2 and herpes simplex virus thymidine kinase. Ear: Endocrinol. (2003) 148:73–80.
   PubMed Web of Science ®Google Scholar
• •Development of a retroviral vector co-expressing HSVTK and h/L-2and demonstration of its enhanced efficacy and in vivo bystander effect in DTC and ATC animal models.
   Google Scholar
• PALU G, CAVAGGIONI A, CALVI P et al.: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Thec (1999) 6:330–337.
   PubMed Web of Science ®Google Scholar
• •First clinical trial of cancer gene therapy based on combined delivery of a suicide and a cytokine gene. Demonstration of safety and efficacy in patients with recurrent glioblastoma multiforme.
   Google Scholar
• BARZON L, TACCALITI A, FRAN CHIN E, PACENTI M, BOSCARO M, PALU G: Suicide/cytokine gene therapy in end-stage anaplastic thyroid carcinoma. Mol. Ther. (2002) 5:S386.
   Google Scholar
• •First clinical study of gene therapy in patients with thyroid cancer based on combined delivery of a suicide and a cytokine gene. Treatment was safe.
   Google Scholar
• BACHLEITNER-HOFMANN T, STIFT A, FRIEDL J et al.: Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. .1 Clin. Endocrinol. Metab. (2002) 87:1098–1104.
   Google Scholar
• SCHOTT M, SEISSLER J: Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol. Metab. (2003) 14:156–162.
   PubMed Web of Science ®Google Scholar
• SCHOTT M, SEISSLER J, LETTMANN M, FOUXON V, SCHERBAUM WA, FELDKAMP J: Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. Clin. Endocrinol. Metab. (2001) 86:4965–4969.
   Google Scholar
• •Clinical trial of DC vaccination therapy in patients with metastasing MTC, showing safety and efficacy of treatment.
   Google Scholar
• STIFT A, FRIEDL J, DUBSKY P et al.: Dendritic cell-based vaccination in solid cancer.j Clin. Oncol. (2003) 21:135–142.
   PubMed Web of Science ®Google Scholar
• STIFT A, SACHET M, YAGUBIAN R et al.: Dendritic cell vaccination in medullary thyroid carcinoma. Clin. Cancer Res. (2004) 10:2944–2953.
   PubMed Web of Science ®Google Scholar
• •Clinical trial of DC vaccination therapy in patients with metastasing MTC, showing tumour response in four out of ten treated cases.
   Google Scholar
• POWELL DJ JR, EISENLOHR LC, ROTHSTEIN JL: A thyroid tumor-specific antigen formed by the fusion of two self proteins. J. Immunol. (2003) 170: 861–869.
   PubMed Web of Science ®Google Scholar
• •Investigation of the immunogenicity of RET/PTC3, a thyroid tumour-specific fusion protein expressed in thyroid carcinoma.
   Google Scholar
• SHARKEY MS, LIZEE G, GONZALES MI, PATEL S, TOPALIAN SL: CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. (2004) 64:1595–1599.
   PubMed Web of Science ®Google Scholar
• LAU K, BICKNELL R: Antiangiogenic gene therapy. Gene Thec (1999) 6:1793–1795.
   PubMed Web of Science ®Google Scholar
• YE C, FENG C, WANG S, LIU X, LIN Y, LI M: Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology (2002) 143:3522–3528.
   PubMed Web of Science ®Google Scholar
• BELLETTI B, FERRARO P, ARRA C et al.: Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene (1999) 18:4860–4869.
   PubMed Web of Science ®Google Scholar
• KLICHE S, WALTENBERGER J: VEGF receptor signaling and endothelial function. IUBMB Life (2001) 52:61–66.
   PubMed Web of Science ®Google Scholar
• FONG GH, ROSSANT J, GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376:66–70.
   PubMed Web of Science ®Google Scholar
• GOLDMAN CK, KENDALL RL, CABRERA G et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Nati Acad. Sci. USA (1998) 95:8795–8800.
   PubMed Web of Science ®Google Scholar
• KENDALL RL, THOMAS KA: Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10705–10709.
   PubMed Web of Science ®Google Scholar
• KONG HL, HECHT D, SONG W et al.: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the fit-1 vascular endothelial growth factor receptor. Hum. Gene Ther. (1998) 9:823–833.
   PubMed Web of Science ®Google Scholar
• TAKAYAMA K, UENO H, NAKANISHI Y et al.: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. (2000) 60:2169–2177.
   PubMed Web of Science ®Google Scholar
• YE C, FENG C, WANG S et al.: sFlt- 1 gene therapy of follicular thyroid carcinoma. Endocrinology (2004) 145:817–822.
   PubMed Web of Science ®Google Scholar
• •Transfer of slit-1 gene effectively inhibits the growth of xenografted human FTC thyroid tumours in irnmunodeficient mice.
   Google Scholar
• O'REILLY MS: Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res. (2002) 8:3309–3310.
   Google Scholar
• MAUCERI HJ, HANNA NN, BECKETT MA et al.: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (1998) 394:287–291.
   PubMed Web of Science ®Google Scholar
• HUANG X, WONG MK, YI H et al.: Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res (2002) 62:5727–5735.
   Google Scholar
• YOKOYAMA Y, DHANABAL M, GRIFFIOEN AW, SUKHATME VP, RAMAKRISHNAN S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. (2000) 60:2190–2196.
   PubMed Web of Science ®Google Scholar
• BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274:373–376.
   PubMed Web of Science ®Google Scholar
• PORTELLA G, SCALA S, VITAGLIANO D, VECCHIO G, FUSCO A: ONYX-015, an ElB gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metal,. (2002) 87:2525–2531.
   PubMed Web of Science ®Google Scholar
• •Efficacy of the d/1520 oncolytic adenovirus in an ATC animal model.
   Google Scholar
• PORTELLA G, PACELLI R, LIBERTINI S et al.: ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. Clin. Endocrinol. Metal,. (2003) 88:5027–5032.
   PubMed Web of Science ®Google Scholar
• BERLINGIERI MT, SANTORO M, BATTAGLIA C, GRIECO M, FUSCO A: The Adenovirus ElA gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. Oncogene (1993) 8:249–255.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, CUNNINGHAM C, BUCHANAN A et al.: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Thec (2001) 8:746–759.
   PubMed Web of Science ®Google Scholar
• NAGAYAMA Y, NISHIHARA E, NAMBA H et al.: Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system. Cancer Gene Thec (2001) 8:36–44.
   PubMed Web of Science ®Google Scholar
• SRINIVASAPPA J, GARZELLI C, ONODERA T, RAY U, NOTKINS AL: Virus-induced thyroiditis. Endocrinology (1988) 122:563–566.
   PubMed Web of Science ®Google Scholar
• ATTA MS, IRVING WL, POWELL RJ, TODD I: Enhanced expression of MHC class I molecules on cultured human thyroid follicular cells infected with reovirus through induction of type 1 interferons. Clin. Exp. Immunol. (1995) 101:121–126.
   PubMed Web of Science ®Google Scholar
• NORMAN KL, LEE PW: Reovirus as a novel oncolytic agent. J. Clin. Invest. (2000) 105:1035–1038.
   PubMed Web of Science ®Google Scholar
• STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO (1998) 17:3351–3362.
   PubMed Web of Science ®Google Scholar
• ONODERA T, AWAYA A: Anti-thyroglobulin antibodies induced with recombinant reovirus infection in BALB/c mice. Immunology (1990) 71:581–585.
   PubMed Web of Science ®Google Scholar
• GAULTON GN, STEIN ME, SAFKO B, STADECKER MJ: Direct induction of Ia antigen on murine thyroid-derived epithelial cells by reovirus. Immunol. (1989) 142:3821–3825.
   Web of Science ®Google Scholar
• NEUFELD DS, PLATZER M, DAVIES TF: Reovirus induction of MHC class II antigen in rat thyroid cells. (1989) EndocrMology124:543–545.
   Google Scholar